Ep 199 - CEO Powell explains how RefleXion developed precise targeting system for cancer-killing radiotherapy

Ep 199 - CEO Powell explains how RefleXion developed precise targeting system for cancer-killing radiotherapy
DeviceTalks Weekly
Ep 199 - CEO Powell explains how RefleXion developed precise targeting system for cancer-killing radiotherapy

Jul 12 2024 | 00:54:24

/
Episode 199 • July 12, 2024 • 00:54:24

Hosted By

Tom Salemi

Show Notes

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi interviews Todd Powell, CEO and president of RefleXion, maker of a smart radiotherapy system used to combat cancer. Powell talks about his path into MedTech and how the company’s ScinTix system can “debulk” widespread cancer in patients. This episode is sponsored by the DeviceTalks West conference taking place Oct. 16-17 at the Santa Clara Convention Center. Register at West.DeviceTalks.com Thank you for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

Previous Episode

Ep 198 - Mullings and Bell unpack SRS 2024: Surprises, disappointments and where is surgical robotics headed?

Next Episode

Ep 200 - CEO Rowland shares how Endotronix will bring hope to heart patients following FDA Cordella approval

Other Episodes

September 02, 2022

Ep 116 - How Medtronic CDS is bringing the power of data to bear in the fight against chronic diseases

In this episode, two senior leaders from Medtronic’s Cardiovascular Diagnostics & Services group share the group’s vision of “turning data into the right therapy.”...

Play

00:36:07

October 02, 2020

Ep 29 - Avail Medsystems, AliveCor help surgeons, patients, and sales reps battle COVID through connectivity

In a double dose of New Tools and Technology interviews, co-host Tom Salemi talks with two companies using connective technology to build out innovative...

Play

00:37:03

May 14, 2021

Ep 58 - Getting to the heart of Boston Scientific’s peripheral business; How Hologic sees trials changing

Jeff Mirviss, executive vice president of Boston Scientific’s peripheral business, explains why the specialty’s name doesn’t really reflect the importance of arteries, veins and...

Play

01:17:28